Clinical trial NCT00810472: Functional Antigen Matching in Corneal Transplantation
Official title: Clinical Trial to Investigate Superiority of HLA Matching in Comparison to Random Graft Assignment With Respect to the Endpoint 'Time to First Endothelial Graft Rejection' in Penetrating Keratoplasty.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Corneal Diseases
Keywords: Penetrating keratoplasty
HLA matching
Corneal diseases that require penetrating keratoplasty
Lead sponsor: University Hospital Freiburg
Sponsor class: OTHER
Collaborators: name: German Research Foundation
First posted: 2008-12-18
Enrollment: 650
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Penetrating keratoplasty is one of the most commonly performed transplantation surgeries. Graft rejection is a major complication. HLA compatibility has already been demonstrated an effective prophylaxis in several retrospective investigations. The purpose of the investigators randomized clinical trial is to demonstrate superiority of HLA matching in comparison to random graft assignment with respect to the endpoint 'time to first endothelial graft rejection' in penetrating keratoplasty. The investigators will perform DNA-based allele resolution typing.


Eligibility criteria: Inclusion Criteria:

* Predicted waiting time for a 4/6 match lower than 6 months.

Exclusion Criteria:

* Minority
* Legal incapacity

Primary outcomes:
measure: Time to first endothelial graft rejection.
timeFrame: Mostly within the first six months.
Secondary outcomes:
Other outcomes:
Locations:
city: Freiburg
country: Germany
facility: University Eye Hospital Freiburg
state: Baden-Württemberg
Study officials:
References:
citation: Bohringer D, Spierings E, Enczmann J, Bohringer S, Sundmacher R, Goulmy E, Reinhard T. Matching of the minor histocompatibility antigen HLA-A1/H-Y may improve prognosis in corneal transplantation. Transplantation. 2006 Oct 27;82(8):1037-41. doi: 10.1097/01.tp.0000235908.54766.44.
citation: Reinhard T, Spelsberg H, Henke L, Kontopoulos T, Enczmann J, Wernet P, Berschick P, Sundmacher R, Bohringer D. Long-term results of allogeneic penetrating limbo-keratoplasty in total limbal stem cell deficiency. Ophthalmology. 2004 Apr;111(4):775-82. doi: 10.1016/j.ophtha.2003.07.013.
citation: Reinhard T, Bohringer D, Enczmann J, Kogler G, Mayweg S, Wernet P, Sundmacher R. Improvement of graft prognosis in penetrating normal-risk keratoplasty by HLA class I and II matching. Eye (Lond). 2004 Mar;18(3):269-77. doi: 10.1038/sj.eye.6700636.
citation: Bohringer D, Reinhard T, Duquesnoy RJ, Bohringer S, Enczmann J, Lange P, Claas F, Sundmacher R. Beneficial effect of matching at the HLA-A and -B amino-acid triplet level on rejection-free clear graft survival in penetrating keratoplasty. Transplantation. 2004 Feb 15;77(3):417-21. doi: 10.1097/01.TP.0000110415.10401.94.
citation: Reinhard T, Bohringer D, Enczmann J, Kogler G, Wernet P, Bohringer S, Sundmacher R. HLA class I/II matching and chronic endothelial cell loss in penetrating normal risk keratoplasty. Acta Ophthalmol Scand. 2004 Feb;82(1):13-8. doi: 10.1046/j.1600-0420.2003.00188.x.
citation: Bohringer D, Reinhard T, Enczmann J, Godehard E, Sundmacher R. Individual analysis of expected time on the waiting list for HLA-matched corneal grafts. Dev Ophthalmol. 2003;36:50-5. doi: 10.1159/000067648.
citation: Bohringer D, Grotejohann B, Ihorst G, Reinshagen H, Spierings E, Reinhard T. Rejection Prophylaxis in Corneal Transplant. Dtsch Arztebl Int. 2018 Apr 13;115(15):259-265. doi: 10.3238/arztebl.2018.0259.
citation: Bohringer D, Ihorst G, Grotejohann B, Maurer J, Spierings E, Reinhard T; FANCY study group. Functional antigen matching in corneal transplantation: matching for the HLA-A, -B and -DRB1 antigens (FANCY) - study protocol. BMC Ophthalmol. 2014 Dec 13;14:156. doi: 10.1186/1471-2415-14-156.